Alphamab Oncology (9966)

Currency in HKD
10.24
-0.74(-6.74%)
Closed·
9966 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
9966 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.1411.30
52 wk Range
2.1611.30
Key Statistics
Bid/Ask
10.22 / 10.24
Prev. Close
10.24
Open
11.3
Day's Range
10.14-11.3
52 wk Range
2.16-11.3
Volume
4.53M
Average Volume (3m)
4.24M
1-Year Change
369.23%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9966 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.00
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Alphamab Oncology News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Alphamab Oncology Company Profile

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of advanced malignant solid tumors, lung cancer, and breast cancer; KN019, an immunosuppressive agent in Phase II clinical trial for prophylaxis of organ rejection in adult patients receiving a kidney transplant; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops pre-clinical stage products for oncology comprising JSKN022, JSKN027, JSKN021, JSKN020, and JSKN028 for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.

Compare 9966 to Peers and Sector

Metrics to compare
9966
Peers
Sector
Relationship
P/E Ratio
54.9x−29.4x−0.6x
PEG Ratio
0.310.230.00
Price/Book
5.0x7.7x2.6x
Price / LTM Sales
14.3x21.6x3.3x
Upside (Analyst Target)
−29.9%−7.1%39.0%
Fair Value Upside
Unlock−15.3%4.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.00

Earnings

Latest Release
Apr 28, 2025
EPS / Forecast
0.21 / --
Revenue / Forecast
466.52M / --
EPS Revisions
Last 90 days

9966 Income Statement

People Also Watch

169.00
9926
-0.29%
123.91
PDD
-3.35%
207.15
GOOGL
-0.64%

FAQ

What Stock Exchange Does Alphamab Trade On?

Alphamab is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Alphamab?

The stock symbol for Alphamab is "9966."

What Is the Alphamab Market Cap?

As of today, Alphamab market cap is 8.74B.

What Is Alphamab's Earnings Per Share (TTM)?

The Alphamab EPS (TTM) is 0.17.

From a Technical Analysis Perspective, Is 9966 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alphamab Stock Split?

Alphamab has split 0 times.

How Many Employees Does Alphamab Have?

Alphamab has 420 employees.

What is the current trading status of Alphamab (9966)?

As of 26 Aug 2025, Alphamab (9966) is trading at a price of 10.24, with a previous close of 10.24. The stock has fluctuated within a day range of 10.14 to 11.30, while its 52-week range spans from 2.16 to 11.30.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.